Heart failure: What's new

In this episode, Rob Doughty focuses on what's new in New Zealand's treatment of heart failure.

Topics

intro
Play now
case study
Play now
terminology and definitions
Play now
why is it important to consider ejection fraction
Play now
what more do we want to know? Why it’s important to classify his heart failure
Play now
what are we looking for during the examination?
Play now
what tests should we consider?
Play now
further investigations
Play now
adding another medication- what should we choose and why?
Play now
protocol for switching medications
Play now
would T2D change our management?
Play now
option to self-fund
Play now
evidence base for SGLT-2i use in heart failure?
Play now
how do we introduce them to his current medication regime?
Play now
what about monitoring?
Play now
what else do we need to consider?
Play now
final option - consideration of heart transplantation
Play now
take-home messages
Play now

Take home messages

Heart failure is modifiable
Therapeutic interventions can make a huge difference over the years ahead for individuals
Polypharmacy - Medication classes mean a lot
It’s all about the dose
Don’t forget the AF – feel the pulse

Resources

Guidelines for the Prevention, Detection, and Management of Heart Failure Heart Lung and Circulation (2018)
Guidance update for SGLT2 inhibitors New Zealand Formulary
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis ESC Heart Fail (2021)

Patient Resources

Presenter

Rob Doughty

Cardiologist

Rob holds the Heart Foundation Chair of Heart Health at the University of Auckland where he runs a programme of research related to improving the understanding of the causes, prevention and treatment of heart disease in NZ. He is a cardiologist at the Green Lane Cardiovascular Service, Auckland City Hospital and The Heart Group.